{"id":3562,"date":"2020-11-26T10:51:02","date_gmt":"2020-11-26T10:51:02","guid":{"rendered":"https:\/\/www.lifescienceart.com\/?p=3562"},"modified":"2020-11-26T10:51:02","modified_gmt":"2020-11-26T10:51:02","slug":"malaria-vaccine-mosquirix-first-but-imperfect","status":"publish","type":"post","link":"https:\/\/www.lifescienceart.com\/ro\/science\/medicine\/malaria-vaccine-mosquirix-first-but-imperfect\/","title":{"rendered":"Vaccinul \u00eempotriva malariei: Progres major, cu unele rezerve"},"content":{"rendered":"

Vaccinul \u00eempotriva malariei: Un progres major cu unele rezerve<\/h2>\n\n

Context<\/h2>\n\n

Malaria, o boal\u0103 transmis\u0103 de \u021b\u00e2n\u021bari, r\u0103m\u00e2ne o amenin\u021bare semnificativ\u0103, \u00een special \u00een Africa, unde ucide un copil \u00een fiecare minut. Oamenii de \u0219tiin\u021b\u0103 \u0219i autorit\u0103\u021bile din domeniul s\u0103n\u0103t\u0103\u021bii publice au f\u0103cut progrese \u00een combaterea malariei, \u00eens\u0103 c\u0103utarea unui vaccin eficient este \u00een curs.<\/p>\n\n

Mosquirix: primul vaccin \u00eempotriva malariei<\/h2>\n\n

Compania farmaceutic\u0103 GlaxoSmithKline, cu finan\u021bare de la Funda\u021bia Bill \u0219i Melinda Gates, a dezvoltat un vaccin numit Mosquirix (RTS,S), care a trecut recent de un obstacol major de reglementare. Agen\u021bia European\u0103 pentru Medicamente (EMA) a recomandat vaccinul ca fiind sigur \u0219i eficient pentru utilizare la copiii cu risc din Africa.<\/p>\n\n

Eficacitate \u0219i provoc\u0103ri<\/h2>\n\n

De\u0219i aprobarea Mosquirix este un pas important \u00eenainte, este important de men\u021bionat c\u0103 vaccinul nu este la fel de eficient precum se spera ini\u021bial. \u00centr-un studiu clinic amplu, a redus episoadele de malarie cu aproximativ o treime la copiii mici din Africa subsaharian\u0103, nereu\u0219ind s\u0103 ating\u0103 \u021binta de eficacitate de 50% \u0219i fiind departe de eficacitatea de 95% dorit\u0103 de obicei pentru vaccinuri.<\/p>\n\n

\u00cen plus, Mosquirix necesit\u0103 administrarea a trei doze la copii. \u00cen timp, eficacitatea sa scade, fiind necesar\u0103 o doz\u0103 de rapel. Ace\u0219ti factori ridic\u0103 \u00eengrijor\u0103ri cu privire la analiza cost-beneficiu a vaccinului, \u00een special \u00een mediile cu resurse limitate.<\/p>\n\n

C\u00e2nt\u0103rirea riscurilor \u0219i beneficiilor<\/h2>\n\n

\u00cen ciuda limit\u0103rilor, EMA a stabilit c\u0103 beneficiile Mosquirix dep\u0103\u0219esc riscurile. Vaccinul este cel mai avansat \u00een curs de dezvoltare, iar GlaxoSmithKline lucreaz\u0103 deja la o versiune de a doua genera\u021bie.<\/p>\n\n

Exper\u021bii recunosc c\u0103 chiar \u0219i un vaccin par\u021bial eficient ar putea avea un impact semnificativ \u00een reducerea poverii malariei. Pentru copiii care sufer\u0103 anual de mai multe episoade severe de malarie, vaccinul le-ar putea schimba via\u021ba.<\/p>\n\n

Urm\u0103torii pa\u0219i<\/h2>\n\n

Organiza\u021bia Mondial\u0103 a S\u0103n\u0103t\u0103\u021bii (OMS) va decide acum dac\u0103 recomand\u0103 utilizarea Mosquirix \u0219i va oferi \u00eendrum\u0103ri cu privire la implementarea acestuia. Ulterior, \u021b\u0103rile vor lua propriile decizii cu privire la adoptarea vaccinului.<\/p>\n\n

Progresul \u0219i viitorul<\/h2>\n\n

De\u0219i Mosquirix nu este un vaccin perfect, reprezint\u0103 un progres semnificativ \u00een lupta \u00eempotriva malariei. Eforturile continue de cercetare \u0219i dezvoltare ale GlaxoSmithKline promit viitorul dezvolt\u0103rii de vaccinuri mai eficiente \u0219i mai convenabile \u00eempotriva malariei.<\/p>\n\n

Dac\u0103 procesul de aprobare decurge f\u0103r\u0103 probleme, primele doze de Mosquirix ar putea fi disponibile pentru copii \u00een 2017, oferind o nou\u0103 speran\u021b\u0103 \u00een lupta \u00eempotriva acestei boli devastatoare.<\/p>","protected":false},"excerpt":{"rendered":"

Vaccinul \u00eempotriva malariei: Un progres major cu unele rezerve Context Malaria, o boal\u0103 transmis\u0103 de \u021b\u00e2n\u021bari, r\u0103m\u00e2ne o amenin\u021bare semnificativ\u0103, \u00een special \u00een Africa, unde ucide un copil \u00een fiecare…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[359],"tags":[3706,6750,2133,178,2862],"class_list":["post-3562","post","type-post","status-publish","format-standard","hentry","category-medicine","tag-malaria","tag-mosquirix","tag-global-health","tag-public-health","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/posts\/3562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/comments?post=3562"}],"version-history":[{"count":1,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/posts\/3562\/revisions"}],"predecessor-version":[{"id":3563,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/posts\/3562\/revisions\/3563"}],"wp:attachment":[{"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/media?parent=3562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/categories?post=3562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/ro\/wp-json\/wp\/v2\/tags?post=3562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}